Strides Arcolab Ltd has informed BSE that the Members of the Company, by way of postal ballot, have approved the Special Resolutions, with requisite majority:
1. Inter-Corporate investment under section 372A of the Companies Act, 1956 for investment of upto Rs 60 crores in Onco Therapics Ltd.
2. Inter-Corporate investment under section 372A of the Companies Act, […]

Strides Arcolab Ltd has informed BSE that the Company has allotted 10,45,725 fully paid equity shares of Rs 10/- each at a price of Rs 400/- per share, against conversion of equivalent number of Fully Convertible Debentures, to Blissup Holdings Ltd.
Consequent to the allotment, the paid up equity share capital of the Company has increased […]

Strides Arcolab Ltd has informed BSE regarding a Press Release dated May 14, 2008 titled “Strides Arcolab receives ANDA approval for Flumazenil Injection USF, 0.1 mg / ml multiple dose vial.”
Press Release:
“Strides Arcolab today announced receipt of ANDA approval for Flumazenil Injection USP. 0.1 mg / ml multiple dose vial.
The product is licensed to Akorn-Strides, […]

Strides Arcolab Ltd has informed BSE about Press Release titled “Strides Arcolab receives 2 ANDA approvals for Ondansetron Injection USP, 2 mg/ml (20 ml vials) and 2 mg/ml (2 ml vials).
Press Release :
“Stride Arcolab today announced receipt of 2 ANDA approval for Ondansctron Injection USP, 2 mg/ml (20 ml vials) and 2 mg/ml (2 ml […]

With reference to the news item appearing in a news channel on ‘dilution of stake by Promoters’ and ‘bidding by Nicholas Piramal’ group, Strides Arcolab Ltd has clarified to BSE that the Company strongly deny any such development and wish to state that the news is not factual and is purely speculative.
On the contrary, the […]

Strides Arcolab Ltd has informed BSE that the Remuneration Committee of the Company on March 31, 2008 has granted 6,00,000 options under the Strides Arcolab ESOP 2006 at Rs 133/- per option (exercise price), to few Eligible Employees of the Company. The shares covered by such options are 6,00,000 equity shares.
The vesting period of these […]

Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials.
The product is licensed to Akom-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akom, Inc [NASDAQ: AKRX] and Strides Arcolab Ltd.
Fosphenytoin is the third approval amongst 22 sterile […]

Strides Arcolab Ltd on March 11, 2008 has announced that its penicillin sterile manufacturing site in Bangalore has been classified as acceptable by the USFDA for manufacturing sterile products for the US market. The facility was approved with no FDA-483 observations.
In a statement, Mr. Arun Kumar ? Vice Chairman and Group CEO of Strides Arcolab […]

Strides Arcolab Ltd on March 12, 2008 has announced its second ANDA approval for Tobramycin 40 mg/mL.
The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn, Inc and Strides Arcolab Ltd.
Tobromycin is the second approval amongst 22 sterile submissions the Company has submitted with US FDA.
Mr. […]

Strides Arcolab Ltd on March 12, 2008 has announced its second ANDS approval from Health Canada for Tazo Pip Sterile Injection in three presentations.
The product is licensed to an undisclosed partner in Canada and the Company expects to launch the product immediately.
Pip Taz is amongst the various sterile submissions the Company has submitted with Health […]